Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib + PD-1 Inhibitor +/- Chemotherapy in Advanced Cholangiocarcinoma with FGFR2 Fusions/Rearrangements
NCT07786766Phase 2Recruiting
- Sponsor
- Purinomia Biotech
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in cholangiocarcinoma (CCA), sponsored by Purinomia Biotech. Started Aug 2026; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07786766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07786766.